Company

PegBio Co., Ltd.

PegBio is a biopharmaceutical company developing long-acting peptide drugs for diabetes and obesity, listed in Hong Kong in May 2025.

About

Founded in 2008 as Suzhou PegBio Medical Co., Ltd., PegBio Co., Ltd. is a biopharmaceutical company based in Hangzhou, China, developing innovative drugs for diabetes and obesity. Its pipeline includes long-acting peptide drugs such as PB-119, PB-718 and PB-401. The company completed its initial public offering on the Hong Kong Stock Exchange in May 2025.

5Funding rounds

9Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in